Tagged with Clinical Trials,

Biotech The CEO of Venter Pharma explains the challenges of bringing a diagnostic drug to the market, and how they hope to leverage the science behind their product, LacTEST, in various new forms and indications.   Before you came on board at Venter Pharma, the research for your product LacTEST was…

university The executive director of Latin America’s largest plasma fractionation plant, a publicly-funded laboratory within the 400 year old National University of Cordoba, discusses the organization’s social responsibility as a provider and leader for plasma derived therapies in the region, and their exciting pipeline of innovative biotech products.     How does Hemoderivados’s…

doing business Montse Planas was appointed as General Manager of Fresenius Kabi Spain just as the financial crisis went into a downward spin. Today she discusses the efforts the company made to respond to the crisis, and ways in which cost-cutting could be implemented in Spain.   What were some of the…

biotech The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million since 2006, and strives to deliver its pipeline of innovative medicines to treat seriously ill patients in Mexico.   You…

biotech The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million since 2006, and strives to deliver its pipeline of innovative medicines to treat seriously ill patients in Mexico.   You…

strategy Long-term strategy is the name of the game for Janssen. Alejandro Smolje, the company’s director of finance for Latin America South, outlines how that strategy is implemented in Argentina and highlights the affiliate’s emphasis on its clinical research and its impact on Argentina’s healthcare environment.   What have been some…

clinical trials The Mexico country manager of the Swiss biopharmaceutical company discusses the recent restructuring process the subsidiary has been going through, the strategic importance of Mexico as a logistic and clinical research hub for the region as well as how the company is going digital.     In the past ten…

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials “Clinical trials are an area where we want to build capabilities, both internally and externally” says Novartis Malaysia’s president and managing director. Novartis, with 22 ongoing trials, is one of the leaders in Malaysia and clearly understands the benefits as the government is promoting trials through the healthcare NKEA.  …

clinical trials Klinsel’s CEO discusses the company’s ambitions of growth in a very competitive CRO market and stresses that local experience is truly a distinguishing factor and this is why they are already partnering and performing trials for one of the country’s largest local manufacturers.     Klinsel was appointed last year…

commercialization The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina.   Could you please provide an historical overview of Argenomics? Several years ago, during my time as an employee of a multinational pharma company, I met a medical doctor and a…